Announce topline results for the COMPASS PWS Phase 3 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Feb 2025
- Due
- 30 Jun 2026
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“followed by the announcement of topline results in the first half of 2026”
What we found
Evidence strength A What the grades mean
The company announced the topline results for the COMPASS PWS study in September 2025, which occurred before the first half of 2026 deadline.
-
A Acadia Pharmaceuticals Inc. 10-K filed 2026-02-26
“In September 2025, we announced top-line results from our COMPASS PWS study, a Phase 3 study evaluating the efficacy and safety of ACP-101” ✓ confirmed on the page
Market reaction: the shares moved -7.7% against the S&P 500 over the three sessions around the disclosure (25 Feb 2026 to 2 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -181 days
- 2 versions
-
Version 1 · original · stated 26 Feb 2025
Deadline 30 Jun 2026 (“the first half of 2026”)
-
Version 2 · stated 7 May 2025
Deadline 31 Dec 2025 (“early Q4 2025”) · wording expected
“topline results now expected in early Q4 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Announce
- Deliverable
- COMPASS PWS Phase 3 study topline results
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ACAD-002592 · Corrections policy